Zimmer Biomet Holdings (ZBH) Reports In-Line Q4 EPS; Guides Q1 Modestly Below the Street
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
Zimmer Biomet (ZBH) PT Raised to $138 at Baird on 4Q Report; 'Revenues Shows Signs of Stabilization'
January 31, 2018 8:18 AM ESTBaird raised its price target on Zimmer Biomet (NYSE: ZBH) to $138.00 (from $130.00) while maintaining a Outperform rating, following the company's fourth quarter earnings report.
Analyst Jeff Johnson notes a positive outlook on the shares, as ZBH reported fourth revenues above consensus... More
Zimmer Biomet (ZBH) PT Raised to $146 at Leerink Partners
January 31, 2018 7:50 AM ESTLeerink Partners raised its price target on Zimmer Biomet (NYSE: ZBH) to $146.00 (from $142.00) while maintaining a Outperform rating.
Analyst Richard Newitter commented, "Our OP rating is predicated on the view that for longer-term oriented investors we believe ZBH is a turnaround... More
Zimmer Biomet (ZBH) PT Raised to $155 at Needham & Company
January 30, 2018 1:11 PM ESTNeedham & Company raised its price target on Zimmer Biomet (NYSE: ZBH) to $155.00 (from $144.00) while maintaining a Strong Buy rating following in-line Q4 results.
Analyst Mike Matson commented, "ZBH's 4Q17 revenue beat and EPS met consensus and 1Q18 guidance was below consensus. Margins... More
